(September 8, 2017) Through its ongoing ‘AMORE, ITALIA, FOLONARI’ campaign, Folonari Wines has partnered this year with Ovarian Cancer Research Alliance. Joining forces with OCRFA gives Folonari a national platform to continue their fight against ovarian cancer with the ‘Time to Teal with Folonari’ campaign. Frederick Wildman and Sons will working together with its trade … Continued
(August 31, 2017) In answer to the persisting need for a cure to one of the deadliest diseases facing women today, Newk’s Eatery is calling on partners and patrons across its 115 restaurants to “Join the Fight” against ovarian cancer. During Ovarian Cancer Awareness Month this September, guests both dining in or ordering online are … Continued
(July 27, 2017) Earlier this week, in Nature Cell Biology, researchers at The Wistar Institute published their findings about a few strategies to treat clear cell carcinoma. Clear cell is a rare form of ovarian cancer that does not usually respond well to platinum-based chemotherapy, which leaves patients with few options. In most cases of … Continued
Largest private funder of ovarian cancer research recognizes top researchers and community leaders NEW YORK — Today, Ovarian Cancer Research Alliance (OCRFA), the nation’s leading ovarian cancer research, advocacy and patient support organization, announces this year’s winners of its research and survivor awards at its annual conference. OCRFA honors two outstanding researchers for their cutting-edge … Continued
(July 6, 2017) OCRFA is pleased to announce we have once again earned a 4-star rating from Charity Navigator, America’s largest independent charity evaluator. This rating, the highest awarded by Charity Navigator, demonstrates OCRFA’s continued commitment to maintaining responsible fiscal management practices, as well as transparency and accountability, as we continue to strive toward a cure for ovarian … Continued
The White House has released a proposed budget for FY2018 that makes drastic cuts to the budgets for the National Institute of Health (NIH) and Centers for Disease Control and Prevention (CDC). These cuts would reduce the NIH budget by 20% and threaten to halt breakthrough medical research advancements and delay life-saving cures. The proposed … Continued
(May 2, 2017) A study, published in Gynecologic Oncology, revealed the importance of tumor antigen NY-ESO-1 for ovarian cancer patients. This tumor antigen, although not normally found in healthy cells, is very prevalent in tumors such as epithelial ovarian cancers. Over the course of the 14 year study, Roswell Park tested 1,000 ovarian cancer patients … Continued
(April 25, 2017) Researchers from Roswell Park Cancer Institute used data from 15 different studies that were part of the Ovarian Cancer Association Consortium, partially funded by OCRFA, to examine the relationship between epithelial ovarian cancer and hypertension, heart disease, diabetes, and the medications associated with those diseases. After reviewing over 7,600 cases, it was … Continued
A study published in Nature Genetics has identified nine new susceptibility loci, or disease-associated alleles, for different epithelial ovarian cancer (EOC) histotypes and three susceptibility loci within BRCA1 and 2 mutation carriers with EOC. Researchers, including former OCRFA grantee and current OCRFA Scientific Advisory Committee Member Andrew Berchuck, looked at data from 25,509 EOC cases … Continued
(March 6, 2017) A team from University of Texas MD Anderson Cancer Center, including OCRFA Scientific Advisory Committee Member Dr. Robert Coleman, published a study in Journal of Clinical Oncology about the effect of hormonal therapy on a rare type of ovarian cancer. The use of hormone maintenance therapy (HMT) with low-grade serous carcinoma (LGSC), … Continued
(February 7, 2017) An OCRFA funded study, published on January 13, 2017 in Oncotarget, sheds light on EMSY, a gene that researchers at New York University Langone Medical Center now understand to have a role similar to those of BRCA1 and BRCA2. BRCA1 and BRCA2 are well known genes that, when working, help with DNA … Continued
(February 3, 2017) Results from the ARIEL2 trial, funded in part by OCRFA’s grant to the Stand Up to Cancer Ovarian Cancer Dream Team, were recently published in The Lancet. The goal of the trial was to test if the efficacy of rucaparib, an oral PARP inhibitor, was dependent on the type of tumor mutation. … Continued
Get email updates about research news, action alerts, and ways to join the fight.
